一分钟看懂
这是一项关于结直肠癌的II 期 / III 期研究，登记的药物或干预包括Pumitamig；FOLFOX；FOLFIRI；Bevacizumab；CAPOX，当前状态为招募中。登记地点显示中国合肥、重庆、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pumitamig；FOLFOX；FOLFIRI；Bevacizumab；CAPOX · II 期 / III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Local Institution - 0595 · 合肥
- Chongqing University Cancer Hospital · 重庆
- Local Institution - 0354 · 福州
- Fujian Medical University Union Hospital · 福州
- Guangdong Provincial People's Hospital · 广州
- Sun Yat-sen University Cancer Center · 广州
- The Sixth Affiliated Hospital of Sun Yat-sen University · 广州
- Local Institution - 0650 · 深圳
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Local Institution - 0390 · 天津
- Local Institution - 0353 · 哈尔滨
- Nanyang City Center Hospital · 南阳
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Hubei Cancer Hospital · 武汉
- The Third Xiangya Hospital of Central South University · 长沙
- Local Institution - 0411 · 长沙
- Northern Jiangsu People's Hospital · 扬州
- Local Institution - 0381 · 南昌
- Local Institution - 0352 · 沈阳
- Local Institution - 0355 · 沈阳
- Local Institution - 0382 · 济南
- Local Institution - 0378 · 上海
- First Affiliated Hospital of Shanxi Medical University · 太原
- Sichuan Cancer hospital · 成都
- Local Institution - 0360 · 杭州
- Local Institution - 0383 · 杭州
- Local Institution - 0409 · 北京
- Local Institution - 0457 · 杭州
- Local Institution - 0416 · 南京
- Local Institution - 0356 · 上海
公开的入选条件
- * Participant must previously untreated, histologically confirmed recurrent or metastatic colorectal adenocarcinoma, not amenable to curative surgery.
- * Participant must have no known presence of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) per historical results (a validated test should be used).
- * Participant must have no known presence of the gene that encodes the protein B-Raf (BRAF) V600E mutation per local testing.
- * Participant must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Exclusion Criteria
- * Participant must not have any untreated known central nervous system (CNS) metastases including brain, leptomeningeal and/or spinal cord compression.
- * Participant must not have any prior malignancy active within the previous 2 years, except for locally curable cancers that have been apparently cured and considered to be of low risk of recurrence.
- * Participant must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis or cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, and/or ≥ 100 dias
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07221357；登记信息更新于 2026-09-14。